Genicular Nerve Block in Juvenile Idiopathic Arthritis
Status:
Completed
Trial end date:
2021-02-15
Target enrollment:
Participant gender:
Summary
N=104 juvenile idiopathic arthritis patients diagnosed after ILAR criteria with unilateral
persistent knee arthritis. They will be randomly assigned into two groups; group 1 will
receive genicular nerve block, group 2 intra-articular triamcinolone. Both groups will be
examined by SOLAR ultrasound scoring system, Visual analogue scale and Lysholm score at 0, 2
and 12 weeks. A semi-quantitative score will be used to assess tenderness and swelling at the
same intervals.